GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

116 calculators match

Most used

21
MELD-NaAssesses the severity of chronic liver diseaseChild-Pugh ScoreAssesses the prognosis of chronic liver disease, mainly cirrhosisFIB-4 IndexLiver fibrosis scoring indexAPRIAST to platelet ratio — liver fibrosisMaddrey's DFAlcoholic hepatitis severityGlasgow-BlatchfordUpper GI bleed risk stratificationGAHSGlasgow alcoholic hepatitis scoreMontreal IBDIBD classification — CD & UCMayo ScoreUlcerative colitis activityBISAP ScoreBedside index for severity of pancreatitisCLIF-SOFAOrgan failure scoring in cirrhosisAlcohol ContentStandard drinks & alcohol grams calculatorAARC-ACLFAcute-on-chronic liver failure gradePELD / CR ScorePediatric end-stage liver diseaseHarvey-BradshawCrohn's disease activity indexCTSICT severity index — pancreatitisRockall ScoreGI bleed rebleeding & mortality riskCAGEAlcohol use disorder screening (4 questions)MELD 3.0Updated MELD — sex-inclusive formulaAUDIT ScoreAlcohol use disorders identification testVOCAL-Penn ScorePost-operative mortality risk in cirrhosis surgery

Liver & Cirrhosis

17
ALBI GradeAlbumin-bilirubin liver function grade in HCCUKELD ScoreUK model for end-stage liver diseaseMELD-XIMELD excluding INR — for anticoagulated patientsWest Haven CriteriaHepatic encephalopathy gradingMilan CriteriaLiver transplant eligibility in hepatocellular carcinomaLI-RADS v2018 (CT/MRI)Liver observation category from size, APHE and major featuresBCLC StagingHepatocellular carcinoma stage and treatment allocationSimplified AIH CriteriaSimplified criteria for autoimmune hepatitisRevised Original AIH ScoreIAIHG 1999 comprehensive autoimmune hepatitis scoreSAAGSerum-ascites albumin gradient — cause of ascitesR FactorHepatocellular vs cholestatic pattern in liver injuryCLIF-C ACLFMortality prediction in acute-on-chronic liver failureKing's College CriteriaTransplant criteria in acute liver failureGALAD ScoreHCC detection from gender, age, AFP-L3, AFP and DCPMetroticket 2.0AFP-adjusted up-to-seven for HCC transplant eligibilityRUCAMCausality in drug- and herb-induced liver injuryBaveno VII CriteriacACLD, CSPH and sparing screening endoscopy

Fibrosis & MASLD

8
NAFLD Fibrosis ScoreAdvanced fibrosis probability in MASLD/NAFLDBARD ScoreBMI, AST/ALT ratio, diabetes — MASLD fibrosisFatty Liver IndexPredicts hepatic steatosis from routine labsFibrotic NASH Index (FNI)At-risk NASH probability from AST, HbA1c and HDLNAFLD Activity Score (NAS)Histologic activity grade — steatosis, inflammation, ballooningMEFIB IndexMRE + FIB-4 rule for significant fibrosis (≥F2) in MASLDFAST ScoreFibroScan-AST — at-risk NASH from LSM, CAP and ASTSAFE ScoreSteatosis-Associated Fibrosis Estimator for MASLD in primary care

Pancreas & Biliary

8
Ranson's CriteriaAcute pancreatitis severity at 48 hoursGlasgow-Imrie CriteriaAcute pancreatitis severity — the PANCREAS criteriaHAPSHarmless acute pancreatitis scoreTokyo Guidelines — CholangitisTG18 diagnosis and severity grade for acute cholangitisTokyo Guidelines — CholecystitisTG18 diagnosis and severity grade for acute cholecystitisBiliary Pain (Rome IV)Rome IV — defining biliary-type pain before interventionFunctional Pancreatic SODRome IV — pancreatic sphincter of Oddi disorderRevised Atlanta ClassificationAcute pancreatitis severity — mild, moderately severe, severe

IBD

9
Truelove & Witts CriteriaAcute severe ulcerative colitis — admission decisionUCEISUlcerative colitis endoscopic index of severitySCCAISimple clinical colitis activity index — symptoms onlyCDAICrohn's disease activity index — the trial standardSES-CDEndoscopic severity in Crohn's diseasePUCAIPaediatric ulcerative colitis activity indexTravis (Oxford) CriteriaDay 3 colectomy risk in acute severe ulcerative colitisHo IndexDay 3 steroid failure risk in acute severe ulcerative colitisRutgeerts ScorePostoperative Crohn's recurrence at ileocolonoscopy

GI Bleeding

7
EVendo ScorePredicts oesophageal varices needing treatmentForrest ClassificationPeptic ulcer bleeding — rebleeding risk at endoscopyAIMS65 ScoreUpper GI bleed mortality — five bedside criteriaOakland ScoreSafe-discharge risk for acute lower GI bleedingABC ScoreAge, blood tests, comorbidities — GI bleed mortalitySarin ClassificationEndoscopic classification of gastric varicesEGUS (Gastric Ulcer)Malignancy risk in a gastric ulcer, and who needs repeat endoscopy

Alcohol

2
ABIC ScoreAge, bilirubin, INR, creatinine — alcoholic hepatitisLille ModelSteroid response at day 7 in alcoholic hepatitis

Upper GI

4
Chicago Classification v4.0Oesophageal motility pattern from high-resolution manometryLA Classification (Oesophagitis)Los Angeles grade A–D for erosive oesophagitisPrague C & M CriteriaCircumferential and maximal extent of Barrett's oesophagusEREFS (Eosinophilic Oesophagitis)Endoscopic reference score — oedema, rings, exudates, furrows, stricture

Colorectal

3
Boston Bowel Prep ScaleColonoscopy preparation adequacy by segmentStool Osmotic GapOsmotic vs secretory diarrhoea from stool electrolytesATLAS Score (C. difficile)Predicted response to therapy in Clostridioides difficile infection

Functional GI

37
Bristol Stool ScaleStool form types 1–7 and colonic transitRome IV Criteria for IBSIrritable bowel syndrome diagnosis and subtypeFunctional ConstipationRome IV — two of six items, IBS excludedOpioid-Induced ConstipationRome IV — constipation tied to opioid therapyFunctional DiarrhoeaRome IV — loose stools without predominant painFunctional Bloating / DistensionRome IV — bloating without other bowel disorder criteriaUnspecified Functional Bowel DisorderRome IV — bowel symptoms fitting no other categoryCentrally Mediated Abdominal Pain (CAPS)Rome IV — continuous pain unrelated to gut eventsNarcotic Bowel SyndromeRome IV — opioid-induced hyperalgesia of the gutFaecal Incontinence (Rome IV)Rome IV — the criteria, and why nobody is askedFunctional Anorectal PainLevator ani, unspecified pain and proctalgia fugaxFunctional Defecation DisordersRome IV — dyssynergia and inadequate propulsionInfant RegurgitationRome IV — the happy spitter, and the alarm features that rule it outInfant ColicRome IV — recurrent unexplained crying in a well infant under 5 monthsInfant DyscheziaRome IV — straining before a soft stool, and why not to intervenePaediatric Functional ConstipationRome IV — two of six over one month, with overflow soiling as a criterionToddler's DiarrhoeaRome IV functional diarrhoea of childhood — painless, thriving childPaediatric Cyclic Vomiting SyndromeRome IV — both age bands, with different criteria for eachPaediatric Rumination SyndromeRome IV — infant and child/adolescent criteriaFunctional Nausea & Vomiting (Children)Rome IV — two separate disorders that can be met togetherAerophagiaRome IV — distension that increases through the dayPaediatric Functional DyspepsiaRome IV — four times a month, with PDS and EPS subtypingPaediatric Irritable Bowel SyndromeRome IV — plus the constipation clause clinicians missAbdominal MigraineRome IV — stereotypical incapacitating episodes weeks apartFunctional Abdominal Pain — NOSRome IV — the residual category, reached after the other threeNonretentive Faecal IncontinenceRome IV — soiling without retention, where laxatives make it worseFunctional DyspepsiaRome IV — with PDS and EPS subtypingRumination SyndromeRome IV — effortless regurgitation without retchingCyclic Vomiting SyndromeRome IV — stereotypical episodic vomitingCannabinoid HyperemesisRome IV — CVS pattern relieved by cannabis cessationChronic Nausea & VomitingRome IV — chronic nausea and vomiting syndromeBelching DisordersRome IV — supragastric vs gastric belchingFunctional HeartburnRome IV — heartburn with normal acid exposureReflux HypersensitivityRome IV — normal acid exposure, positive symptom associationFunctional Chest PainRome IV — non-cardiac, non-reflux chest painGlobusRome IV — painless lump-in-throat sensationFunctional DysphagiaRome IV — dysphagia with normal endoscopy and manometry
  1. Calculators
  2. /
  3. UCEIS
IBD

UCEIS

Ulcerative colitis endoscopic index of severity

Scores the worst-affected area seen at flexible sigmoidoscopy. Three descriptors, each defined explicitly — which is what makes it more reproducible than the single-judgement Mayo endoscopic subscore.

When to use
Use the UCEIS to quantify mucosal disease at any sigmoidoscopy or colonoscopy performed for ulcerative colitis — at diagnosis, to document endoscopic activity during a flare, to confirm mucosal healing as a treatment target, and to grade severity in acute severe colitis where a higher score carries prognostic weight. Score only the worst-affected area within the segment examined, not an average of the whole colon. It measures the endoscopic dimension of disease alone, so it is read alongside a clinical index such as the SCCAI or the clinical components of the Mayo score rather than in place of them.
Why use it
Because the endoscopic component of ulcerative colitis assessment was for decades the least reproducible part: the Mayo endoscopic subscore compresses the whole mucosal appearance into a single 0–3 judgement with no written anchors, so two endoscopists frequently disagree, and the contentious middle grades (friability, whether it belongs in grade 1 or 2) are where they disagree most. The UCEIS was built to fix exactly that by decomposing the appearance into three separately defined descriptors, each level spelled out, which raises inter-observer agreement and makes the score usable as a trial endpoint and a treat-to-target measure.
Formula, evidence and interpretation

About the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

The UCEIS grades the endoscopic severity of ulcerative colitis on a 0–8 scale by adding three explicitly defined descriptors scored at the single worst-affected segment seen at flexible sigmoidoscopy: vascular pattern (0–2), bleeding (0–3), and erosions and ulcers (0–3). A total of 0–1 is endoscopic remission or near-normal mucosa, 2–4 is mild-to-moderate activity, and 5–8 is severe. Its advantage over the older Mayo endoscopic subscore is reproducibility: each level of each descriptor carries a written definition, so the same appearance scores the same way between different endoscopists — the three descriptors together account for about 90% of the variance in an experienced endoscopist's overall severity judgement.

On this page

  • Formula
  • Interpreting the result
  • Inputs
  • What it returns
  • How it is calculated
  • Facts & figures
  • Evidence
  • How it compares
  • Pearls & pitfalls
  • Critical actions
  • Why it exists
  • About the creator
  • Limitations
  • If you are the patient
  • FAQ
  • Related calculators
  • References

Formula

UCEIS = vascular pattern (0–2) + bleeding (0–3) + erosions and ulcers (0–3)
vascular pattern
0 normal arborisation, 1 patchy obliteration, 2 complete obliteration.
bleeding
0 none, 1 mucosal, 2 luminal mild, 3 luminal moderate or severe.
erosions and ulcers
0 none, 1 erosions, 2 superficial ulcer, 3 deep ulcer.
  • Score the single worst-affected area within the segment examined, not an average across the colon.
  • Each descriptor level has a precise written definition in the source paper — that is the point of the index, and where its reproducibility comes from.
  • The range is 0–8. It is a simple unweighted sum; no descriptor is multiplied.

Interpreting the result

A UCEIS of 0–1 represents endoscopic remission or near-normal mucosa and, when it matches clinical remission, supports continuing maintenance therapy toward the treat-to-target goal of mucosal healing. Scores of 2–4 indicate mild-to-moderate endoscopic activity that persists as a driver of relapse even if symptoms have settled, so it argues for optimising rather than de-escalating therapy. A score of 5–8 is severe endoscopic activity; in an acute severe presentation a UCEIS at the top of the range (7–8) marks patients who will almost all need infliximab or ciclosporin beyond steroids. As an endoscopic measure it is interpreted together with the clinical picture — a low clinical index with a high UCEIS is exactly the symptom-inflammation mismatch that objective monitoring exists to catch.

ScoreBandWhat it meansAction
0–1Remission / minimalEndoscopic remission or near-normal mucosaContinue maintenance therapy; record as a baseline for future endoscopies
2–4Mild to moderateMild-to-moderate endoscopic activity — an ongoing relapse driverOptimise therapy toward endoscopic healing rather than symptom control alone
5–8SevereSevere endoscopic activity; UCEIS 7–8 in acute severe colitis predicts need for rescue therapyAssess against Truelove and Witts criteria, exclude CDI and CMV, involve surgery early

What the UCEIS needs (3 inputs)

Vascular pattern
Normal with clear arborisation (0), patchy obliteration (1), or complete obliteration (2).
Bleeding
None (0), mucosal — coagulated blood on the surface (1), luminal mild — some free liquid blood (2), or luminal moderate/severe — frank blood or oozing after washing (3).
Erosions and ulcers
None (0), erosions ≤ 5 mm (1), superficial ulcer > 5 mm (2), or deep excavated ulcer with a raised edge (3).

What it returns

UCEIS total
The sum of the three descriptors, from 0 to 8.
Activity band
Remission/minimal, mild-to-moderate, or severe.

How it is calculated

The index was derived from a library of 670 video sigmoidoscopies spanning the full range of disease, from which ten endoscopic descriptors were first defined and then narrowed to the three that carried almost all the information. A mixed regression model showed that vascular pattern, bleeding, and erosions and ulcers together explained about 90% of the variance in investigators' overall severity assessment on a 100-point visual analogue scale — the remaining seven candidate descriptors added little once these three were included. Each surviving descriptor was given explicit level definitions so that scoring depends on a written rule rather than a gestalt impression, which is what a subsequent reliability study set out to confirm.

Facts & figures

The three descriptors and their range
DescriptorLevelsRange
Vascular patternNormal / patchy / obliterated0–2
BleedingNone / mucosal / luminal mild / luminal moderate-severe0–3
Erosions and ulcersNone / erosions / superficial ulcer / deep ulcer0–3

Total range 0–8, scored at the worst-affected area. The three descriptors together explained about 90% of the variance in overall endoscopic severity in the derivation study.

Evidence

Derivation — Travis (development)

2012 · n = 670

A two-phase study using a library of 670 video sigmoidoscopies from patients with Mayo Clinic scores of 0–11, supplemented by videos of people without UC and of hospitalised acute severe cases. Investigators first agreed definitions for ten endoscopic descriptors, then rated overall severity on a 0–100 visual analogue scale, and a mixed regression model selected the descriptors that best predicted it.

The final three descriptors — vascular pattern, bleeding, and erosions and ulcers, each with precise definitions — explained about 90% of the variance in the overall assessment of endoscopic severity, with predictions ranging from 4 (normal) to 93 (worst) on the 100-point scale.

Reliability and initial validation — Travis

2013 · n = 57

A new library of 57 flexible-sigmoidoscopy videos assessed by 25 investigators (each rating 28 videos, including duplicates to measure intra-observer reliability), blinded to clinical details except for selected duplicates used to test whether knowing symptoms changed scoring.

UCEIS scores correlated with overall severity at 0.93, Cronbach α was 0.86, and intra- and inter-observer reliability ratios were 0.96 and 0.88. Intra-observer κ for the total was 0.72 and inter-observer κ 0.50; the UCEIS accounted for a median of 86% of the variability in overall severity, and scoring was unaffected by knowledge of clinical details.

Prognosis in acute severe colitis — Corte

2015 · n = 89

89 patients with acute severe ulcerative colitis (Truelove and Witts criteria), all given intravenous hydrocortisone, with the admission UCEIS related to rescue therapy, colectomy and readmission.

A higher UCEIS was associated with worse outcomes; when the admission UCEIS was 7 or 8, almost all patients needed infliximab or ciclosporin beyond steroids, marking a possible threshold for an early rescue-therapy decision.

How it compares

UCEIS vs Mayo endoscopic subscore

The UCEIS is the more reproducible endoscopic measure because every level is defined; the Mayo endoscopic subscore is simpler and more familiar but its single 0–3 judgement disagrees more often between endoscopists.

The Mayo endoscopic subscore packs the whole mucosal appearance into one 0–3 grade with no written anchors, which is quick but leaves the friable middle grades open to interpretation. The UCEIS breaks the appearance into three defined descriptors and sums them 0–8, raising inter-observer agreement. Studies comparing the two report that the UCEIS reflects clinical outcomes and long-term prognosis at least as well as, and by some measures better than, the Mayo endoscopic subscore — which is why the UCEIS is increasingly the endoscopic endpoint of choice in trials.

Open the Mayo endoscopic subscore calculator →Ikeya K, Hanai H, Sugimoto K, et al. The Ulcerative Colitis Endoscopic Index of Severity more accurately reflects clinical outcomes and long-term prognosis than the Mayo endoscopic score. J Crohns Colitis. 2016;10(3):286-295.

UCEIS vs Simple Clinical Colitis Activity Index (SCCAI)

The UCEIS measures mucosal inflammation at endoscopy; the SCCAI measures symptoms without endoscopy — they are complementary, and the mismatch between them is often the clinically useful finding.

The SCCAI is a symptom-only index scored in clinic or by the patient, while the UCEIS requires sigmoidoscopy and grades the mucosa directly. Symptoms and endoscopic activity diverge frequently in ulcerative colitis, so a patient can feel well with a UCEIS still showing active inflammation, or report symptoms with a healed mucosa. Modern treat-to-target management uses the SCCAI for frequent, cheap monitoring and the UCEIS to confirm the endoscopic healing that predicts durable remission.

Open the Simple Clinical Colitis Activity Index (SCCAI) calculator →

Pearls & pitfalls

  • Score only the worst-affected area within the segment examined. Averaging across the colon is a common error and is not how the index was derived.
  • The value of the UCEIS is in its written level definitions — score against them rather than by overall impression, which is precisely the habit the index was built to replace.
  • It is an endoscopic measure only. A UCEIS in remission with active symptoms, or active mucosa with settled symptoms, is a real and clinically important mismatch, not a scoring error.
  • Bleeding is the least reproducible of the three descriptors (the lowest κ in the validation study); take particular care to distinguish mucosal from luminal blood and to wash before scoring.
  • In acute severe colitis a UCEIS of 7–8 is prognostically meaningful — treat it as an early prompt toward rescue therapy rather than a number recorded for completeness.

Critical actions

  • Record the UCEIS at every endoscopy so successive studies have a comparable, reproducible baseline rather than free-text impressions.
  • Read the UCEIS alongside a clinical index (SCCAI or the clinical Mayo items); do not act on the endoscopic score in isolation.
  • In an acute severe presentation, use a high UCEIS to prompt assessment against the Truelove and Witts criteria and early exclusion of Clostridioides difficile and cytomegalovirus.
  • Aim for endoscopic healing (UCEIS 0–1) as the treatment target, not merely symptomatic improvement.
  • Where UCEIS and symptoms disagree, investigate the discrepancy rather than averaging the two.

Why this score exists

The developers' explicit aim was reproducibility, not novelty of content. Endoscopists already recognised vascular pattern, bleeding and ulceration as the features that mattered; what was missing was agreement on how to score them, and the derivation study documented the problem directly — 76% agreement on a 'severe' appearance but only 27% on 'normal'. By writing a definition for every level of every descriptor and discarding the seven candidate features that added nothing once these three were in the model, the authors traded a richer but noisier picture for a lean index that different endoscopists would score the same way, which is the property a trial endpoint or a treat-to-target measure actually needs.

About the creator

  • Simon P. L. Travis

    First author, 2012 derivation and 2013 validation studies

    Led the work that decomposed endoscopic severity into three explicitly defined descriptors, specifically to make scoring reproducible between endoscopists.

  • William J. Sandborn

    Senior author

    Co-authored the derivation and validation, and has led much of the work on trial endpoints in inflammatory bowel disease.

Limitations

  • It captures only the worst-affected area of the segment examined, so it does not describe disease extent or the distribution of inflammation along the colon.
  • It is an endoscopic measure and carries no clinical, laboratory or histological information; histological activity can persist when the UCEIS reads remission.
  • Bleeding, one of the three descriptors, has the lowest inter-observer agreement, so scores can still differ where blood is the dominant feature.
  • The 0–8 total is not linearly tied to a specific management action across its whole range; the bands are a practical grouping, and the acute-severe prognostic threshold (7–8) comes from a specific inpatient population.
  • It was derived and validated in adults; its performance as a paediatric endoscopic measure is less established.

If you are the patient

The UCEIS is a score doctors use during a camera test (sigmoidoscopy or colonoscopy) to measure how inflamed the lining of the bowel is in ulcerative colitis. They look at three things at the most affected spot — the blood-vessel pattern in the lining, whether there is any bleeding, and whether there are erosions or ulcers — and add them up to a number between 0 and 8. A score of 0 or 1 means the lining looks healed or almost normal, the middle range means some active inflammation, and a high score means severe inflammation. Because how you feel and how the lining looks do not always match, your team may use this score alongside your symptoms to decide whether treatment is working and whether it needs changing.

Frequently asked questions

What is the UCEIS and what does it score?#

The Ulcerative Colitis Endoscopic Index of Severity grades mucosal inflammation on a 0–8 scale from three descriptors seen at endoscopy: vascular pattern (0–2), bleeding (0–3), and erosions and ulcers (0–3), scored at the worst-affected area.

What UCEIS score means remission?#

A UCEIS of 0–1 is endoscopic remission or near-normal mucosa. Scores of 2–4 indicate mild-to-moderate activity and 5–8 indicate severe activity.

How is the UCEIS different from the Mayo endoscopic subscore?#

The Mayo endoscopic subscore is a single 0–3 judgement of the whole appearance; the UCEIS breaks it into three separately defined 0–2 and 0–3 descriptors summed to 0–8. Because each level has a written definition, the UCEIS is more reproducible between endoscopists.

Do you score the whole colon or one area?#

Only the single worst-affected area within the segment examined. The UCEIS was derived that way; averaging across the colon is not how the score is meant to be applied.

Does a high UCEIS predict needing surgery?#

In acute severe colitis it carries prognostic weight — a UCEIS of 7 or 8 on admission identifies patients who almost all go on to need rescue therapy with infliximab or ciclosporin beyond steroids, and it is associated with higher colectomy rates.

What are the three UCEIS descriptors?#

Vascular pattern, bleeding, and erosions and ulcers. Each is scored separately at the most severely affected area seen, and the three are summed. Crucially, all three are defined by published descriptors with agreed wording, which is what gives the UCEIS its reproducibility advantage over a single global impression.

What is the range of the UCEIS?#

Three to eleven when the descriptors are scored on their original scales, though the index is frequently reported on a 0 to 8 scale where each descriptor starts at zero. The two conventions describe the same assessment but produce different numbers, so a UCEIS quoted without saying which scale was used is ambiguous — record the convention alongside the score.

Is the UCEIS validated for measuring treatment response?#

Yes, and that is a meaningful advantage over the Mayo endoscopic subscore. The UCEIS was developed with formal attention to inter-observer variability and has been shown to be responsive to change, which makes it usable as a trial endpoint and for judging whether therapy has worked endoscopically. The Mayo endoscopic subscore is a single four-point global rating with poorer reproducibility, particularly at the boundary between scores of 0 and 1 that now defines endoscopic remission.

Related calculators

  • Mayo Score — Ulcerative colitis activity
  • Truelove & Witts Criteria — Acute severe ulcerative colitis — admission decision
  • SCCAI — Simple clinical colitis activity index — symptoms only
  • PUCAI — Paediatric ulcerative colitis activity index
  • Travis (Oxford) Criteria — Day 3 colectomy risk in acute severe ulcerative colitis

References

Original / primary reference

  1. Travis SPL, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61(4):535-542.

Validation and prognosis

  1. Travis SPL, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145(5):987-995.
  2. Corte C, Fernandopulle N, Catuneanu AM, et al. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis. 2015;9(5):376-381.
  3. Ikeya K, Hanai H, Sugimoto K, et al. The Ulcerative Colitis Endoscopic Index of Severity more accurately reflects clinical outcomes and long-term prognosis than the Mayo endoscopic score. J Crohns Colitis. 2016;10(3):286-295.

Guidelines

  1. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106.

Last updated July 30, 2026. Clinical knowledge base written and curated by GastroAGI Team from primary medical literature.

Written from primary literature and not yet independently clinically reviewed.

For use by qualified healthcare professionals. This calculator supports clinical judgement and does not replace it.